id,gene_symbol,protein_name,tier,evidence_priority,has_structure,surface_class,pdb_count_total,alphafold_mean_pLDDT,has_cryoEM,has_activation_state_pdb_pair,activation_state_pdb_active,activation_state_pdb_inactive,has_known_aptamer,aptamer_count_pubmed,aptamer_pmids,in_cev_map,opentargets_top_disease_name,opentargets_top_disease_score
P00813,ADA,Adenosine deaminase,Tier 1.5,0.957,1,A_surface,2,96.56,0,0,,,1,72,"42012076,41877526,41762796,41635914,40403280,40189053,39856849,39847085,36796307,33998617,32043202,30876536,30060448,27589406,26606306,25597304,25521724,25360869,24976151,24893272,24682016,24035856,23462984,23202335,23037591,22944024,22613226,41910181,41791686,41267360,39673485,39396299,38583236,36855421,34241023,33147453,32546280,30926472,26605646,24624989,23373863,22543727,20345118,19381549,19378312,18293985,17440909,17000903,16856187,16619330",1,Severe combined immunodeficiency due to adenosine deaminase deficiency,0.8556816060494579
P51795,CLCN5,H(+)/Cl(-) exchange transporter 5,Tier 1.5,0.955,1,A_surface,2,80.62,0,0,,,0,0,,1,Dent disease type 1,0.850724240157394
P25189,MPZ,Myelin protein P0,Tier 1.5,0.951,1,A_surface,2,81.69,0,0,,,0,0,,1,Charcot-Marie-Tooth disease type 1B,0.8377022197539885
P36888,FLT3,Receptor-type tyrosine-protein kinase FLT3,Tier 1.5,0.949,1,A_surface,11,75.94,0,0,,,1,6,"41733039,34364920,31434881,30237882,29299123,22411871",1,acute myeloid leukemia,0.8313389209288576
P13473,LAMP2,Lysosome-associated membrane glycoprotein 2,Tier 1.5,0.948,1,A_surface,2,83.19,0,0,,,0,0,,1,Glycogen Storage Disease Type 2b,0.8273010649608126
P04626,ERBB2,Receptor tyrosine-protein kinase erbB-2,Tier 1.5,0.934,1,A_surface,63,74.0,0,0,,,1,119,"41836728,41744190,41540559,41494763,41413339,41321156,41297941,40851486,40761795,40494827,40403699,40382399,40223744,40220375,40120226,40080161,40056884,39873777,39809083,39756158,39748051,39643321,39609809,39539244,39263860,39233482,39177424,38901393,38813974,38789508,38693181,38679242,38604040,38409854,38066021,37729138,37659641,37591183,37522239,37392577,37038354,36272296,36255496,36001395,35504229,34952586,34476602,34236165,33876310,33627408",1,non-small cell lung carcinoma,0.7789523142843545
O94856,NFASC,Neurofascin,Tier 1.5,0.933,1,A_surface,2,76.31,0,0,,,0,0,,1,neurodevelopmental disorder with central and peripheral motor dysfunction,0.7782432580663833
Q15746,MYLK,"Myosin light chain kinase, smooth muscle",Tier 1.5,0.93,1,A_surface,7,65.88,0,0,,,0,0,,1,"aortic aneurysm, familial thoracic 7",0.7659842793171938
P24394,IL4R,Interleukin-4 receptor subunit alpha,Tier 1.5,0.923,1,A_surface,10,54.75,0,0,,,1,3,"32751068,27819142,22282665",1,asthma,0.742115080702623
P16671,CD36,Platelet glycoprotein 4,Tier 1.5,0.921,1,A_surface,1,93.94,0,0,,,1,6,"41713143,41140242,39762152,33596054,33291667,31904170",1,platelet-type bleeding disorder 10,0.7360571429413174
Q02413,DSG1,Desmoglein-1,Tier 1.5,0.92,1,A_surface,1,62.06,0,0,,,0,0,,1,severe dermatitis-multiple allergies-metabolic wasting syndrome,0.7335328506238418
P09758,TACSTD2,Tumor-associated calcium signal transducer 2,Tier 1.5,0.919,1,A_surface,7,82.69,0,0,,,1,4,"41384307,41241473,40050871,39250993",1,gelatinous drop-like corneal dystrophy,0.7293087728162646
P08637,FCGR3A,Low affinity immunoglobulin gamma Fc region receptor III-A,Tier 1.5,0.912,1,A_surface,15,85.69,0,0,,,1,2,"41249026,21531729",1,autosomal recessive primary immunodeficiency with defective spontaneous natural killer cell cytotoxicity,0.7061437347032623
Q13555,CAMK2G,Calcium/calmodulin-dependent protein kinase type II subunit gamma,Tier 1.5,0.891,1,A_surface,2,78.38,0,0,,,0,0,,1,intellectual developmental disorder 59,0.6354497016986491
Q92956,TNFRSF14,Tumor necrosis factor receptor superfamily member 14,Tier 1.5,0.879,1,A_surface,8,79.94,0,0,,,0,0,,1,diffuse large B-cell lymphoma,0.5983171413833771
P01597,IGKV1-39,Immunoglobulin kappa variable 1-39,Tier 1.5,0.876,1,A_surface,2,90.5,0,0,,,0,0,,1,cutaneous Leishmaniasis,0.5868213846274001
P01764,IGHV3-23,Immunoglobulin heavy variable 3-23,Tier 1.5,0.876,1,A_surface,6,91.0,0,0,,,0,0,,1,cutaneous Leishmaniasis,0.5868213846274001
P23083,IGHV1-2,Immunoglobulin heavy variable 1-2,Tier 1.5,0.876,1,A_surface,1,91.75,0,0,,,0,0,,1,cutaneous Leishmaniasis,0.5868213846274001
P01593,IGKV1D-33,Immunoglobulin kappa variable 1D-33,Tier 1.5,0.876,1,A_surface,6,90.88,0,0,,,0,0,,1,cutaneous Leishmaniasis,0.5868213846274001
P06312,IGKV4-1,Immunoglobulin kappa variable 4-1,Tier 1.5,0.876,1,A_surface,10,90.62,0,0,,,0,0,,1,cutaneous Leishmaniasis,0.5868213846274001
Q96D96,HVCN1,Voltage-gated hydrogen channel 1,Tier 1.5,0.865,1,A_surface,2,69.75,0,0,,,0,0,,1,Joubert syndrome,0.5504227269701596
Q9P1W8,SIRPG,Signal-regulatory protein gamma,Tier 1.5,0.864,1,A_surface,2,85.5,0,0,,,0,0,,1,type 1 diabetes mellitus,0.5457344827318543
O15155,BET1,BET1 homolog,Tier 1.5,0.864,1,A_surface,1,83.06,0,0,,,0,0,,1,neurodegenerative disease,0.5468418315282804
P34741,SDC2,Syndecan-2,Tier 1.5,0.863,1,A_surface,1,60.84,0,0,,,0,0,,1,COVID-19,0.5422254875204983
P15260,IFNGR1,Interferon gamma receptor 1,Tier 1.5,0.862,1,A_surface,5,66.0,0,0,,,1,2,33667716,1,disseminated atypical mycobacterial infection,0.5414012388034828
O00161,SNAP23,Synaptosomal-associated protein 23,Tier 1.5,0.859,1,A_surface,2,82.12,0,0,,,0,0,,1,neurodegenerative disease,0.5288361677964304
P21926,CD9,CD9 antigen,Tier 1.5,0.858,1,A_surface,5,88.56,0,0,,,1,17,"41999228,41625383,40618375,39266887,38866706,38057814,37585601,37351166,37019008,36704890,34647460,34505435,33304477,32730952,32207293,28959386",1,diphtheria,0.5261379875719714
P54756,EPHA5,Ephrin type-A receptor 5,Tier 1.5,0.858,1,A_surface,2,79.38,0,0,,,0,0,,1,neurodegenerative disease,0.5261379875719714
Q9HCM2,PLXNA4,Plexin-A4,Tier 1.5,0.856,1,A_surface,1,83.06,0,0,,,0,0,,1,neurodegenerative disease,0.518371001420808
P13591,NCAM1,Neural cell adhesion molecule 1,Tier 1.5,0.852,1,A_surface,7,79.5,0,0,,,1,1,36649818,1,smoking initiation,0.5071020926446286
P15814,IGLL1,Immunoglobulin lambda-like polypeptide 1,Tier 1.5,0.85,1,A_surface,3,75.06,0,0,,,0,0,,1,isolated agammaglobulinemia,0.4996673834185043
P18084,ITGB5,Integrin beta-5,Tier 1.5,0.846,1,A_surface,3,82.19,0,0,,,0,0,,1,migraine disorder,0.48652455084344876
A1L3X0,ELOVL7,Very long chain fatty acid elongase 7,Tier 1.5,0.828,1,A_surface,1,89.75,0,0,,,0,0,,1,substance-related disorder,0.4271436896798171
Q92854,SEMA4D,Semaphorin-4D,Tier 1.5,0.828,1,A_surface,2,80.81,0,0,,,0,0,,1,skin aging,0.4259843235238637
P20702,ITGAX,Integrin alpha-X,Tier 1.5,0.825,1,A_surface,9,88.0,0,0,,,0,0,,1,neurodegenerative disease,0.41708750879240836
Q9P121,NTM,Neurotrimin,Tier 1.5,0.824,1,A_surface,2,82.38,0,0,,,1,2,"35699468,26194558",1,smoking initiation,0.41382172436739945
Q14242,SELPLG,P-selectin glycoprotein ligand 1,Tier 1.5,0.82,1,A_surface,1,50.38,0,0,,,1,1,25979951,1,glaucoma,0.40058604767334977
P08571,CD14,Monocyte differentiation antigen CD14,Tier 1.5,0.818,1,A_surface,1,84.75,0,0,,,1,14,"41636061,41542672,41140242,38477735,38280803,37162508,36716100,36475636,32589412,32515246,30900705,30563044,25483705,12498773",1,dengue disease,0.39219972762611355
P35080,PFN2,Profilin-2,Tier 1.5,0.817,1,A_surface,1,95.5,0,0,,,0,0,,1,smoking initiation,0.38873499449725424
Q08554,DSC1,Desmocollin-1,Tier 1.5,0.81,1,A_surface,2,76.75,0,0,,,0,0,,1,atopic eczema,0.3674657640592667
O95255,ABCC6,ATP-binding cassette sub-family C member 6,Tier 1.5,0.809,1,A_surface,4,80.94,0,0,,,0,0,,0,Pseudoxanthoma elasticum,0.864631668818611
O75144,ICOSLG,ICOS ligand,Tier 1.5,0.803,1,A_surface,2,82.56,0,0,,,0,0,,1,immunodeficiency 119,0.34184658238916177
P30968,GNRHR,Gonadotropin-releasing hormone receptor,Tier 1.5,0.799,1,A_surface,1,84.19,0,0,,,0,0,,0,hypogonadotropic hypogonadism,0.83100005285263
P10912,GHR,Growth hormone receptor,Tier 1.5,0.799,1,A_surface,9,58.69,0,0,,,1,5,"38811951,38477735,31603904",0,Laron syndrome,0.8304020079647765
Q13308,PTK7,Inactive tyrosine-protein kinase 7,Tier 1.5,0.796,1,A_surface,1,82.69,0,0,,,1,110,"41949051,41786503,41782379,41780252,41473803,41172349,41097888,41065179,41047832,40987771,40652441,40618375,40556592,40488675,40479736,40415219,40388621,40274545,40033943,39933564,39583320,39468753,39405917,39315658,39226482,39211579,39161311,39127174,38985770,38922365,38889444,38773263,38708542,38695582,38642044,38466380,38359901,38148412,38064592,37974961,37480788,37473438,37458448,37247456,37105082,37003060,36765879,36722904,36722696,36471380",1,neurodegenerative disease,0.3194172724024113
O75015,FCGR3B,Low affinity immunoglobulin gamma Fc region receptor III-B,Tier 1.5,0.795,1,A_surface,6,88.62,0,0,,,0,0,,1,Takayasu arteritis,0.3170299762085396
O43525,KCNQ3,Potassium voltage-gated channel subfamily KQT member 3,Tier 1.5,0.789,1,A_surface,1,56.72,0,0,,,0,0,,0,Benign familial neonatal seizures,0.7961763561533409
P37023,ACVRL1,Activin receptor type-1-like,Tier 1.5,0.789,1,A_surface,7,82.0,0,0,,,0,0,,0,"telangiectasia, hereditary hemorrhagic, type 2",0.7951167515831324
P16410,CTLA4,Cytotoxic T-lymphocyte protein 4,Tier 1.5,0.787,1,A_surface,22,80.12,0,0,,,1,26,"41907643,40972397,40870970,40811947,40536609,39417693,38473398,38158454,36966395,36831533,36603108,36015348,33970170,32929022,32840510,32280743,32024070,31405808,28918052,28082399,26030229,25565435,24892807,23460536,23460531,14612549",0,autoimmune lymphoproliferative syndrome due to CTLA4 haploinsufficiency,0.7906408646569979
Q13698,CACNA1S,Voltage-dependent L-type calcium channel subunit alpha-1S,Tier 1.5,0.786,1,A_surface,2,71.81,0,0,,,0,0,,0,"hypokalemic periodic paralysis, type 1",0.7869997029542154